NutriBand (NTRB) EBITDA Margin (2018 - 2026)
NutriBand (NTRB) posted EBITDA Margin of 289.42% for Q2 2026, down 13.6% sequentially from 254.78% in Q1 2026, and down 7764.0% YoY from 3.78% in Q2 2025.
NutriBand (NTRB) EBITDA Margin (2018 - 2026) Analysis & Trends
NutriBand has reported EBITDA Margin for 9 years, with the latest figure at 289.42% in Q2 2026.
- Quarterly EBITDA Margin fell 7764.0% year-over-year to 289.42% in Q2 2026, while the trailing twelve-month figure through Apr 2026 was 452.61% (down 4364.0% YoY) and the FY2026 annual result came in at 408.41%, up 7229.0% from the prior year.
- EBITDA Margin slipped to 289.42% in Q2 2026 per NTRB's latest filing, from 254.78% in the prior quarter.
- Over five years, EBITDA Margin peaked at 125.65% in Q3 2023 and troughed at 1121.3% in Q4 2025.
- A 5-year average of 371.52% and a median of 272.1% in 2026 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2025: EBITDA Margin surged 76993 bps in 2022, then slumped 90035 bps in 2025.
- Over 5 years, EBITDA Margin stood at 173.38% in 2022, then plunged by 132 bps to 402.84% in 2023, then surged by 45 bps to 220.94% in 2024, then plunged by 408 bps to 1121.3% in 2025, then soared by 74 bps to 289.42% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 289.42%, 254.78%, and 1121.3% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | NutriBand | 46.38 Mn | 42.37 Mn | 196,801.00 | -289.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -289.42% |
| Jan 31, 2026 | -254.78% |
| Oct 31, 2025 | -1,121.30% |
| Jul 31, 2025 | -321.83% |
| Apr 30, 2025 | -211.78% |
| Jan 31, 2025 | -865.34% |
| Oct 31, 2024 | -220.94% |
| Jul 31, 2024 | -318.35% |
| Apr 30, 2024 | -462.50% |
| Jan 31, 2024 | -249.01% |
| Oct 31, 2023 | -402.84% |
| Jul 31, 2023 | -125.65% |
| Apr 30, 2023 | -213.42% |
| Jan 31, 2023 | -319.13% |
| Oct 31, 2022 | -173.38% |
| Jul 31, 2022 | -226.73% |
| Apr 30, 2022 | -143.51% |
| Jan 31, 2022 | -767.47% |
| Oct 31, 2021 | -543.55% |
| Jul 31, 2021 | -225.62% |